focus -WSS

focus

author：focus 2025-10-03 00:38:43 - browse：88

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Longer MASH drug regimen improved liver, Akero study finds

WSS

Ancient Greek ideas underpin modern concepts of pregnancy

Pregnant women don't need prenatal multivitamins, study concludes

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bring on the sabbaticals for nurses

With Wegovy coverage, Medicare patients may face high costs

'Patient friction coefficient' can gauge a clinical trial's patient burden

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Wildfire smoke exposes gaps in outdoor worker protections

Florida health officials providing scant details on measles cases

United colonoscopy coverage change 'may cost lives,' doctors say

Bring on the sabbaticals for nurses

Virginia high school admissions case could be legal follow

Mirador, a new biotech startup, launches with $400 million

As demand for Covid shots wanes, Moderna seeks its next success

With Wegovy coverage, Medicare patients may face high costs

What does generative AI mean for health care? We asked experts

Pregnant women don't need prenatal multivitamins, study concludes

focus

Adam's Take: Intra

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

With Wegovy coverage, Medicare patients may face high costs

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Readout Newsletter: Illumina, CRISPR, Regeneron

Longer MASH drug regimen improved liver, Akero study finds

hotspot

leisure time

focus

focus